Sanofi's NKCE trial SAR443579 in AML halted early; results posted for terminated study
Sanofi terminated a Phase 1/2 trial of SAR443579 combined with azacitidine and venetoclax in newly diagnosed AML, with results posted after the sponsor's strategic decision to stop.
Sanofi's registry record for NCT06508489 shows one item this week, the posting of results for a terminated trial.
- SAR443579, a CD123-targeting natural killer cell engager, was tested in Substudy 01 in combination with azacitidine and venetoclax in adult patients with newly diagnosed acute myeloid leukemia who were ineligible for intensive chemotherapy. The trial was terminated with the status reason listed as "Early discontinuation based on strategic sponsor decision not driven by any safety concerns."1 Actual enrollment reached 7 participants against a design calling for enrollment, Phase 1/Phase 2, single group assignment, and treatment as the primary purpose.1 The study's primary completion and overall completion dates were both 2025-08-08 (actual), with results first posted on 2026-10-19.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.